title: Galanin and pancreastatin inhibit stimulated insulin secretion in the mouse: comparison of effects.
abstract: The effects of the two intrapancreatic peptides galanin and pancreastatin on basal and stimulated insulin and glucagon secretion in the mouse were compared. It was found that at 2 min after intravenous injection of galanin or pancreastatin (4.0 nmol/kg), basal plasma glucagon and glucose levels were slightly elevated. Galanin was more potent than pancreastatin to elevate basal plasma glucagon levels: they increased from 60 +/- 15 to 145 +/- 19 pg/ml (p less than 0.01) after galanin compared to from 35 +/- 5 to 55 +/- 8 pg/ml (p less than 0.05) after pancreastatin. Plasma insulin levels were lowered by galanin (p less than 0.05), but not by pancreastatin. CCK-8 (6.3 nmol/kg) or terbutaline (3.6 mumol/kg) markedly increased the plasma insulin levels. Galanin (4.0 nmol/kg) completely abolished the insulin response to CCK-8 (p less than 0.001), but pancreastatin (4.0 nmol/kg) was without effect. Galanin inhibited the insulin response to terbutaline by approximately 60% (p less than 0.01), but pancreastatin inhibited the insulin response to terbutaline by approximately 35% only (p less than 0.05). CCK-8 and terbutaline did both elevate plasma glucagon levels by moderate potencies: neither pancreastatin nor galanin could affect these responses. Thus, in the mouse, galanin and pancreastatin both inhibit basal and stimulated insulin secretion, and stimulate basal glucagon secretion. Galanin is thereby more potent than pancreastatin. The study also showed that galanin potently inhibits insulin secretion stimulated by the octapeptide of cholecystokin and by the beta 2-adrenoceptor agonist terbutaline, and that pancreastatin inhibits terbutaline-induced insulin secretion.
authors: Department of Pharmacology, Lund University, Sweden.
authors: S
authors: S
authors: Lindskog
authors: B
authors: B
authors: Ahrén
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D053379:Chromogranin A; D005260:Female; D019004:Galanin; D005934:Glucagon / Q000097:blood / Q000378:metabolism; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D007329:Insulin Antagonists; D000078790:Insulin Secretion; D007700:Kinetics; D051379:Mice; D008815:Mice, Inbred Strains; D009479:Neuropeptides / Q000494:pharmacology*; D010187:Pancreatic Hormones / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D012016:Reference Values; D012844:Sincalide / Q000494:pharmacology; D013726:Terbutaline / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D053379:Chromogranin A; D007328:Insulin; D007329:Insulin Antagonists; D009479:Neuropeptides; D010187:Pancreatic Hormones; D010455:Peptides; C050836:pancreastatin; D019004:Galanin; D005934:Glucagon; D012844:Sincalide; D013726:Terbutaline